Month: June 2021

RPIH publishes its audited annual financial statements for the financial year 2021 The audited annual financial statements for 2021 is available to download at www.realpeoplegroup.co.za. Amended financial covenants Pursuant to the terms and conditions (as amended by a written procedure completed on 21 September 2020) (the “Terms and Conditions“) for the up to SEK 260,000,000 and up to NOK 135,000,000 senior unsecured callable bonds 2013/2028 with ISIN: SE0005392560 and NO0010689342 (the “Bonds“) issued by Real People Investment Holdings Limited (the “Issuer” or “RPIH“), the Issuer shall comply with the undertakings to uphold specified levels of financial ratios for relevant measurement periods from time to time, as prescribed in the senior unsecured loan agreement entered into between the...

NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), an animal health and wellness company, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $5.00 per share. The aggregate gross proceeds to Better Choice from the public offering are expected to be $40 million prior to deducting underwriting discounts, commissions and other estimated offering expenses. Better Choice has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock to cover over-allotments, if any. Better Choice plans to use the net proceeds of this offering for general corporate purposes. Better Choice may also elect to use proceeds from this offering to acquire complimentary...

June 29, 2021Announcement no. 13 Pipeline Update Regarding COVID-19 test BioPorto A/S (BioPorto) is currently developing a point-of-care test for SARS-CoV-2 on the proprietary gRAD platform designed to quickly and easily identify infected patients using a non-invasive sample. While indicative data from the process and studies in the US and Denmark supports the gRAD platforms strong capabilities as a technology for rapid testing, BioPorto has prioritized to secure a high sensitivity of more than 80% to further strengthen the clinical and commercial potential of the platform technology compared to other rapid test formats. “Over the last months we have increased sensitivity in our gRAD-based SARS-CoV-2 samples and studies, especially from the data developed and collected in Aarhus (DK). However, we are not yet at our target of 80%. Therefore,...

TORONTO, June 29, 2021 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) today announced additional assay results from its current drilling program on the Fenelon Gold Property (“Fenelon” or the “Property”). Expansion drilling continues to reveal additional bulk mineable, near-surface mineralized corridors in the western part of Area 51, while definition drilling continues to define steep, high metal factor (gold grade multiplied by thickness) gold shoots within the Tabasco-Cayenne Zones (see 181-, 134- and 086- shoots on Fig. 1). Drilling is currently focusing on multiple areas, within the approximately 1.0 km by 1.2 km central portion of the Fenelon Gold System, to expand and better define the mineralization in support of the maiden mineral resource estimate (“MMRE”). Over 200,000 metres...

LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and...

21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for its tumor infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202. Cohort 3B enrolled patients that had progressed on prior immune checkpoint inhibitor (ICI) therapy, including patients with oncogene-driven tumors who received...

Issy les Moulineaux, 29 June 2021   Caisse Française de Financement Local has decided to issue on 30 June 2021 – EUR 1,000,000 -Fixed Rate Obligations Foncières due 30 June 2031. The dealer of the issue is named as stabilizing manager in the applicable Final Terms.   The Base Prospectus dated 11 June 2021 relating to the Euro Medium Term Notes Programme approved by the Autorité des Marchés Financiers and sent for notification to the Commission de Surveillance du Secteur Financier is available on the website of the issuer (www.caissefrancaisedefinancementlocal.fr), at the registered office of the issuer: 1-3 rue du Passeur de Boulogne – 92130 Issy Les Moulineaux Cedex, France, and at the office of the paying agent indicated in the Base Prospectus.   The Final Terms relating to the issue will be available on the website of the AMF...